Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to <scp>TOPAZ</scp> ‐1 Study Eligibility: A Large Global Analysis in a Real‐World Setting
Federica Lo Prinzi(Campus Bio Medico University Hospital), Gian Paolo Spinelli(Sapienza University of Rome), Elisabetta Fenocchio(Candiolo Cancer Institute), Monica Verrico(Policlinico Umberto I), Oluseyi Abidoye(Mayo Clinic), Emiliano Tamburini(Ospedale Infermi di Rimini), Margherita Rimini(Vita-Salute San Raffaele University), Alessandro Pastorino(Ospedale Policlinico San Martino), Fabian Finkelmeier(Goethe University Frankfurt), Lucrezia Zumstein(Hospital Universitario 12 De Octubre), Alessandro Parisi(Marche Polytechnic University), Gerald W. Prager(Comprehensive Cancer Center Vienna), Lukas Perkhofer(University Hospital Ulm), Giovanni Farinea(University of Turin), Caterina Vivaldi(Scuola Superiore Sant'Anna), Florian Castet(Institut d'Investigació Biomédica de Bellvitge), C. Pinto(Harvard University), Vincenzo Formica(University of Rome Tor Vergata), Ilario Giovanni Rapposelli(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Matteo Landriscina(University of Foggia), Chiara Braconi(Beatson West of Scotland Cancer Centre), Marta Schirripa(Azienda Sanitaria Locale Viterbo), Anna Diana(University of Campania "Luigi Vanvitelli"), Jessica Lucchetti(Campus Bio Medico University Hospital), Maria Grazia Rodriquenz(Casa Sollievo della Sofferenza), Ester Oneda(Fondazione Poliambulanza Istituto Ospedaliero), Salvatore Corallo(Fondazione IRCCS Istituto Nazionale dei Tumori), Ingrid Garajová(University of Parma), Federico Nichetti(Fondazione IRCCS Istituto Nazionale dei Tumori), Frederik Peeters, Antonio Avallone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giuseppe Aprile(Ospedale Santa Maria della Misericordia di Udine), A. Martirena(Hospital Universitario Fundación Jiménez Díaz), David J. Pinato(Hammersmith Hospital), Anna Saborowski(Medizinische Hochschule Hannover), Chiara Pircher(Fondazione IRCCS Istituto Nazionale dei Tumori), Mario Scartozzi(University of Cagliari), Beodeul Kang(CHA University Bundang Medical Center), Hong Jae Chon(CHA University Bundang Medical Center), Nuno Couto(Champalimaud Foundation), Tiziana Pressiani(IRCCS Humanitas Research Hospital), Masafumi Ikeda(National Cancer Center Hospital East), Lorenzo Antonuzzo(Azienda Ospedaliero-Universitaria Careggi), Angela Lamarca(Hospital Universitario Fundación Jiménez Díaz), Il Hwan Kim(Inje University Haeundae Paik Hospital), Michele Ghidini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Jin Won Kim(Seoul National University Bundang Hospital), Emanuela Dell’Aquila(Università Campus Bio-Medico), Stefano Tamberi(Ospedale "Santa Maria delle Croci" di Ravenna), Yoo Changhoon(University of Ulsan)
Cited by 0
Related Papers
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k